Norwegian bladder cancer diagnostics company Photocure ASA (OSE: PHO) said on Wednesday that it has signed an agreement with pharmaceutical services provider Clinigen to supply Hexvix through a Named Patient Program (NPP) in more than 40 markets where the product is not approved or commercially available.
Under the agreement, Photocure will supply Hexvix to Clinigen, which will manage worldwide distribution from a UK-based central warehouse.
Hexvix, marketed as Cysview in the US and Canada, is a drug that preferentially accumulates in bladder cancer cells, making them glow bright pink during blue light cystoscopy (BLC) and is designed to improve tumour detection.
The programme allows physicians to request Hexvix for individual bladder cancer patients, in accordance with local regulations, where they determine that BLC using Hexvix may be beneficial. The global initiative follows an initial rollout in South Africa in 2024 and is intended to provide access for patients with suspected or recurrent bladder tumours in countries where Hexvix is not approved or marketed.
Where approved, BLC with Hexvix is used alongside standard white light cystoscopy to support the diagnosis and management of bladder cancer in patients with known or suspected disease.
According to data cited by the company, bladder cancer accounted for 635,000 new cases and more than 227,000 deaths worldwide in 2024, with approximately 1.98 million prevalent cases over five years.
Akeso submits sNDA for ivonescimab chemotherapy combination in first-line biliary tract cancer
Specialised Therapeutics' YONDELIS sarcoma therapy approved in Thailand
Rezolute's ersodetug meets primary endpoint in Phase 3 upLIFT study of tumour hyperinsulinism
PAI Pharma acquires Nexus Pharmaceuticals
Innovent Biologics presents preclinical data for IL-6/TL1A bispecific antibody IAR177
Guardant Health expands liquid biopsy test with AI-powered epigenomic applications
Nuvation Bio to present at Jefferies Global Healthcare Conference in London